A 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP), Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2) is encoded by the PTPN11 gene. SHP2 participates in a number of signaling pathways, including PI3K-AKT, JAK-STAT, RAS-MAPK, and PD-1/PD-L1. Additionally, SHP2 controls mitochondrial homeostasis to negatively regulate the activation of the recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome. SHP2 has been viewed as a very desirable target for treating human diseases, particularly cancer.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69746 | 3-Azetidinemethanol hydrochloride | 928038-44-2 | 3-Azetidinemethanol HCl is a pharmaceutical intermediate that may be utilized in the preparation /synthesis of SHP2 inhibitors. |
|
V2183 | Batoprotafib (TNO-155) | 1801765-04-7 | TNO155 (TNO-155) is an inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11; IC50=11 nM) with potential anticancer activity. |
|
V69753 | BPDA2 | 2907659-86-1 | BPDA2 is a selective and competitive active site SHP2 inhibitor, with IC50s of 92.0 nM, 33.39 μM, and 40.71 μM for SHP2, SHP1, and SHP1B respectively. |
|
V78677 | CNBCA | CNBCA is a specific, and competitive SHP2 enzyme inhibitor (antagonist) with IC50 of 0.87 μM. | |
|
V98478 | JAB-3312 | 2245082-05-5 | JAB-3312 is an orally available inhibitor of oncogenic phosphatase SHP2 (IC50: 1.9 nM) with anticancer activity. |
|
V50955 | NAT6-297775 | 1348433-02-2 | SHP2 inhibitor |
|
V3210 | NSC-87877 | 56990-57-9 | NSC-87877 (NSC87877) is a novel, potent, cell-permeable small molecule and competitive inhibitor of SHP-1 and SHP-2 PTP (protein tyrosine phosphatase) with anticancer activity. |
|
V51367 | NSC-87877 disodium | 56932-43-5 | SHP-1 and SHP-2 PTP inhibitor |
|
V85833 | PB17-026-01 | ||
|
V41014 | PF-03622905 | 1072100-15-2 | PF-03622905 is a potent ATP-competitive PKC inhibitor (antagonist) with IC50s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ and PKCθ, respectively. |
|
V41013 | PF-04577806 | 1072100-81-2 | PF-04577806 is a specific and ATP-competitive PKC inhibitor. |
|
V69742 | PF-07284892 (ARRY-558) | 2498597-94-5 | PF-07284892 (ARRY-558) is a potent orally bioactive SHP2 inhibitor (antagonist) with IC50 of 21 nM. |
|
V50901 | RMC-0331 | 2488788-52-7 | RMC-0331 is a novel and orally active inhibitor of SOS1. |
|
V5027 | RMC-4550 | 2172651-73-7 | RMC-4550 (RMC4550) is a novel, potent, selective and allosteric inhibitor of SHP2 phosphatase with anticancer activity. |
|
V91784 | SDUY038 | 2892720-11-3 | SDUY038 is an allosteric inhibitor of SHP2 with IC50 of 1.2 μM and KD of 0.29 μM. |
|
V3045 | SHP099 | 1801747-42-1 | SHP099 (SHP-099), identified through HTS and structure-based drug design, is a potent, selective, orally bioavailable, and highly efficacious allosteric inhibitor of SHP2 [Src homology-2 domain containing protein tyrosine phosphatase-2] with anticancer and anti-osteoarthritis activity. |
|
V3046 | SHP099 HCl | 1801747-11-4 | SHP099 HCl, the HCl salt of SHP-099, isan orally bioavailable, and allostericSHP2 inhibitor with antitumor and anti-inflammatory effects. |
|
V69762 | SHP2-IN-13 | 2951854-02-5 | SHP2-IN-13 is a selective and orally bioactive SHP2 “tunnel site” allosteric inhibitor (antagonist) with IC50 of 83.0 nM. |
|
V69748 | SHP2-IN-14 | 2673400-91-2 | SHP2-IN-14 (compound 27) is an orally bioavailable allosteric inhibitor of SHP2 (IC50=7 nM) with anti-tumor activity. |
|
V78898 | SHP2-IN-16 | SHP2-IN-16 (compound 222) is a SHP2 inhibitor (antagonist) with IC50 of 1 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
